59 research outputs found
From two-dimensional to three-dimensional conformal radiotherapy in prostate cancer: An Indian experience
Background: Sparse data from India are available regarding the outcome
of prostate cancer treatment. We report our experience in treating
prostate cancer with radiotherapy (RT). Materials and Methods: This
study included 159 men with locally advanced cancer treated with RT
with or without hormone therapy between 1984 and 2004. The median RT
dose was 70 Gy over 35 fractions. Eighty-five patients received whole
pelvic RT and prostate boost, and 74 patients were treated with
3-dimensional conformal radiotherapy (3DCRT) to prostate and seminal
vesicles alone. Results: The median follow-up was 25 months and the
freedom from biochemical failure for all the patients at 5 years was
76%, disease-free survival (DFS) 59.1%, and overall survival (OAS) was
70.1%. The risk stratification (91% vs 52%, P < 0.03) and RT dose
(72.8% for dose > 66 Gy vs 43.5% for dose < 66 Gy; P = 0.01)
affected the DFS. DFS at 5 years was better in the group receiving
3DCRT to prostate and seminal vesicles (78% vs 51.5%; P = 0.001) and
was reflected in OAS as well (P = 0.01). Conclusion: CRT technique with
dose escalation results in significant benefit in DFS and OAS in
locally advanced prostate cancer
From two-dimensional to three-dimensional conformal radiotherapy in prostate cancer: An Indian experience
Background: Sparse data from India are available regarding the outcome
of prostate cancer treatment. We report our experience in treating
prostate cancer with radiotherapy (RT). Materials and Methods: This
study included 159 men with locally advanced cancer treated with RT
with or without hormone therapy between 1984 and 2004. The median RT
dose was 70 Gy over 35 fractions. Eighty-five patients received whole
pelvic RT and prostate boost, and 74 patients were treated with
3-dimensional conformal radiotherapy (3DCRT) to prostate and seminal
vesicles alone. Results: The median follow-up was 25 months and the
freedom from biochemical failure for all the patients at 5 years was
76%, disease-free survival (DFS) 59.1%, and overall survival (OAS) was
70.1%. The risk stratification (91% vs 52%, P < 0.03) and RT dose
(72.8% for dose > 66 Gy vs 43.5% for dose < 66 Gy; P = 0.01)
affected the DFS. DFS at 5 years was better in the group receiving
3DCRT to prostate and seminal vesicles (78% vs 51.5%; P = 0.001) and
was reflected in OAS as well (P = 0.01). Conclusion: CRT technique with
dose escalation results in significant benefit in DFS and OAS in
locally advanced prostate cancer
Survey of IMRT Practices in Centers Participating in the International Evaluation of Radiotherapy Technology Effectiveness in Cervical Cancer (IntERTECC) Trial
WOS: 000296411701016
- …